Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
CEL SCI Corp (CVM)
The company has Return on Asset of (0.5171) % which means that on every $100 spent on assets, it lost $0.5171. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5825) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -1. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Debt To Assets are very stable compared to the past year. The entity currently falls under 'Micro-Cap' category with a total capitalization of 79.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CEL SCI's market, we take the total number of its shares issued and multiply it by CEL SCI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be fairly valued. CEL SCI Corp shows a prevailing Real Value of $1.41 per share. The current price of the firm is $1.46. Our model approximates the value of CEL SCI Corp from examining the firm fundamentals such as Return On Equity of -1.58, current valuation of 85.5 M, and Shares Outstanding of 53.98 M as well as evaluating its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, in the future, asset prices and their ongoing real values will blend.
Seneca Biopharma (CUR)
The company has Return on Asset of (0.0109) % which means that on every $100 spent on assets, it lost $0.0109. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0251) %, meaning that it generated no profit with money invested by stockholders. Seneca Biopharma's management efficiency ratios could be used to measure how well Seneca Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Nano-Cap' category with a total capitalization of 4.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seneca Biopharma's market, we take the total number of its shares issued and multiply it by Seneca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Flex Pharma (FLKS)
The firm beta is close to zero. Flex Pharma returns are very sensitive to returns on the market. As the market goes up or down, Flex Pharma is expected to follow. The beta indicator helps investors understand whether Flex Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flex deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 444.51 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flex Pharma's market, we take the total number of its shares issued and multiply it by Flex Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Fortress Biotech (FBIO)
The company has return on total asset (ROA) of (0.3768) % which means that it has lost $0.3768 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.9736) %, meaning that it created substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -1.77. At this time, Fortress Biotech's Asset Turnover is very stable compared to the past year. This firm currently falls under 'Micro-Cap' category with a current market capitalization of 34.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fortress Biotech's market, we take the total number of its shares issued and multiply it by Fortress Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Long Term Debt
42.41 Million
At this time, Fortress Biotech's Long Term Debt is very stable compared to the past year.
Fate Therapeutics (FATE)
The company has return on total asset (ROA) of (0.1832) % which means that it has lost $0.1832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3776) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549. The entity currently falls under 'Small-Cap' category with a current market capitalization of 516.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Fate Therapeutics shows a prevailing Real Value of $4.36 per share. The current price of the firm is $4.3. Our model computes the value of Fate Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 113.78 M, profit margin of (2.53) %, and Current Valuation of 262.72 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
AB Corporate Bond (EYEG)
AB Corporate Bond [EYEG] is traded in USA and was established null. The fund is not classified under any group at this time. The fund currently have in assets under management (AUM).
Evoke Pharma (EVOK)
The company has return on total asset (ROA) of (0.4909) % which means that it has lost $0.4909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.3544) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M. This firm currently falls under 'Nano-Cap' category with a current market capitalization of 3.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evoke Pharma's market, we take the total number of its shares issued and multiply it by Evoke Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evoke Pharma is undervalued. Evoke Pharma shows a prevailing Real Value of $2.08 per share. The current price of the firm is $0.4475. Our model computes the value of Evoke Pharma from reviewing the firm fundamentals such as Profit Margin of (1.50) %, current valuation of 4.02 M, and Shares Outstanding of 8.48 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise picking up undervalued instruments and discarding overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Evofem Biosciences (EVFM)
The company has return on total asset (ROA) of (1.2475) % which means that it has lost $1.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8727) %, meaning that it created substantial loss on money invested by shareholders. Evofem Biosciences' management efficiency ratios could be used to measure how well Evofem Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 6.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evofem Biosciences's market, we take the total number of its shares issued and multiply it by Evofem Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Please consider monitoring Macroaxis on a daily basis if you are holding a position in it. Macroaxis is trading at a penny-stock level, and the possibility of delisting is much higher compared to other privates. However, just because the private is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Macroaxis stock to be traded above the $1 level to remain listed. If Macroaxis private price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Macroaxis's Liquidity
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
CEL SCI Corp (CVM)
The company has Return on Asset of (0.5171) % which means that on every $100 spent on assets, it lost $0.5171. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5825) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -1. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Debt To Assets are very stable compared to the past year. The entity currently falls under 'Micro-Cap' category with a total capitalization of 79.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CEL SCI's market, we take the total number of its shares issued and multiply it by CEL SCI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be fairly valued. CEL SCI Corp shows a prevailing Real Value of $1.41 per share. The current price of the firm is $1.46. Our model approximates the value of CEL SCI Corp from examining the firm fundamentals such as Return On Equity of -1.58, current valuation of 85.5 M, and Shares Outstanding of 53.98 M as well as evaluating its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, in the future, asset prices and their ongoing real values will blend.
Seneca Biopharma (CUR)
The company has Return on Asset of (0.0109) % which means that on every $100 spent on assets, it lost $0.0109. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0251) %, meaning that it generated no profit with money invested by stockholders. Seneca Biopharma's management efficiency ratios could be used to measure how well Seneca Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Nano-Cap' category with a total capitalization of 4.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seneca Biopharma's market, we take the total number of its shares issued and multiply it by Seneca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Flex Pharma (FLKS)
The firm beta is close to zero. Flex Pharma returns are very sensitive to returns on the market. As the market goes up or down, Flex Pharma is expected to follow. The beta indicator helps investors understand whether Flex Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flex deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 444.51 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flex Pharma's market, we take the total number of its shares issued and multiply it by Flex Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Fortress Biotech (FBIO)
The company has return on total asset (ROA) of (0.3768) % which means that it has lost $0.3768 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.9736) %, meaning that it created substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -1.77. At this time, Fortress Biotech's Asset Turnover is very stable compared to the past year. This firm currently falls under 'Micro-Cap' category with a current market capitalization of 34.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fortress Biotech's market, we take the total number of its shares issued and multiply it by Fortress Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Long Term Debt
42.41 Million
At this time, Fortress Biotech's Long Term Debt is very stable compared to the past year.
Fate Therapeutics (FATE)
The company has return on total asset (ROA) of (0.1832) % which means that it has lost $0.1832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3776) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549. The entity currently falls under 'Small-Cap' category with a current market capitalization of 516.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Fate Therapeutics shows a prevailing Real Value of $4.36 per share. The current price of the firm is $4.3. Our model computes the value of Fate Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 113.78 M, profit margin of (2.53) %, and Current Valuation of 262.72 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
AB Corporate Bond (EYEG)
AB Corporate Bond [EYEG] is traded in USA and was established null. The fund is not classified under any group at this time. The fund currently have in assets under management (AUM).
Evoke Pharma (EVOK)
The company has return on total asset (ROA) of (0.4909) % which means that it has lost $0.4909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.3544) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M. This firm currently falls under 'Nano-Cap' category with a current market capitalization of 3.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evoke Pharma's market, we take the total number of its shares issued and multiply it by Evoke Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evoke Pharma is undervalued. Evoke Pharma shows a prevailing Real Value of $2.08 per share. The current price of the firm is $0.4475. Our model computes the value of Evoke Pharma from reviewing the firm fundamentals such as Profit Margin of (1.50) %, current valuation of 4.02 M, and Shares Outstanding of 8.48 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise picking up undervalued instruments and discarding overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Evofem Biosciences (EVFM)
The company has return on total asset (ROA) of (1.2475) % which means that it has lost $1.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8727) %, meaning that it created substantial loss on money invested by shareholders. Evofem Biosciences' management efficiency ratios could be used to measure how well Evofem Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 6.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evofem Biosciences's market, we take the total number of its shares issued and multiply it by Evofem Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Bollinger Bands Now
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
